2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types

Wenham, R., Ghamande, S., Makker, V., Hou, J., Duska, L., Matei, D., Bhave, M., Scott, R., Hawk, N., Song, T., & Armstrong, D. K. (2022). 2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types. Ovarian Cancer, A312.3-A313. https://doi.org/10.1136/ijgc-2022-esgo.667

Authors:

Robert M. Wenham

Sharad Ghamande

Vicky Makker

June Y. Hou

Linda Duska

Daniela Matei

Manali Bhave

Rachael Scott

Natalyn Hawk

Tingting Song

Deborah K. Armstrong